Apotheek Godilo
ActiveSummary
Apotheek Godilo has been active since 2005 and the Belgian State Gazette contains no insolvency or warning signals. The 2024 annual accounts show equity of €184k and a net result of €51k. Equity is growing by ~8.9% per year across the filed fiscal years. Its solvency ranks better than 31% of 9623 sector peers (fiscal year 2024). The computed 12-month bankruptcy probability is 0.7% (low).
Checked score
Score 2024
58
/ 100
Fair
The score weighs solvency, liquidity, profitability and financial development. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2023
Profitability60▲+23
Solvency48▲+7
Growth78=
Track record100
Bankruptcy probability, 12 months
0.7%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €10k at 30 days acceptable
Liquidity tight (current ratio 1.39 against 1.3 in 2023; short-term debt: 61.4% and cash: 3.2% of total assets), and 77% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Three signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
neutral · Filed after the deadline
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 28-08-2025, 28 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 10 filingsDeviation from the deadline
2025
not confirmed
2024
28 d late
2023
30 d late
2022
31 d late
2021
31 d late
2020
27 d late
2019
24 d early
← before the deadline
after the deadline →
Checked, nothing found (1)
Financials · fiscal year 2024, abbreviated schema
Equity
€184k▲ 37.9%
2023 · €134k
2018: €93k
2019: €95k
2020: €101k
2021: €116k
2022: €102k
2023: €134k
2018 → 2024
Total assets
€803k▼ 6.2%
2023 · €855k
2018: €622k
2019: €668k
2020: €692k
2021: €678k
2022: €1.14M
2023: €855k
2018 → 2024
Net result
€51k▲ 60.3%
2023 · €32k
2018: €-3k
2019: €2k
2020: €6k
2021: €15k
2022: €-14k
2023: €32k
2018 → 2024
Working capital
€192k▲ 15.7%
2023 · €166k
2018: €217k
2019: €246k
2020: €278k
2021: €91k
2022: €183k
2023: €166k
2018 → 2024
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20202021202220232024Trend
Equity€101k-€116k▲ 15.0%€102k▼ 11.9%€134k▲ 31.0%€184k▲ 37.9%
Operating result€13k-€19k▲ 41.4%€-10k€42k€65k▲ 54.6%
Net result€6k-€15k▲ 162%€-14k€32k€51k▲ 60.3%
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Result per fiscal year
Operating resultNet result
After the dip in 2022 the operating result has climbed two years in a row; 2024 is 55% above 2023 and is the highest result in the available series.
Balance-sheet composition
2024 in colour, 2023 as the grey bar beneath
Assets €803k
Fixed assets
€117k ▼ 15.0%
Current assets
€685k ▼ 4.5%
Equity and liabilities €803k
Equity
€184k ▲ 37.9%
Debt
€618k ▼ 14.3%
Debt's share of the balance-sheet total falls from 84.4% to 77.0%. Equity is higher and debt is lower.
Key figures and ratios
EBITDA
€85k▲
2023 · €62k
Cash flow
€71k▲
2023 · €52k
Current ratio
1.39▲
2023 · 1.30
Quick ratio
1.14▲
2023 · 1.08
Debt to equity
3.36▼
2023 · 5.40
ROE
27.5%▲
2023 · 23.7%
ROA
6.3%▲
2023 · 3.7%
Interest coverage
4.00▲
2023 · 1.64
Debt ≤ 1 year
€493k▼
2023 · €551k
Debt > 1 year
€125k▼
2023 · €171k
Income taxes
€18k▲
2023 · €6k
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Filed annual accounts As filed with the NBB · 2024 against 2023 · 54 lines
Balance sheet
Code20232024
Assets
Total assets20/58€855k€803k▼
Fixed assets21/28€138k€117k▼
Tangible fixed assets22/27€138k€117k▼
Land and buildings22€93k€77k▼
Plant, machinery and equipment23€25k€22k▼
Furniture and vehicles24€2k€1k▼
Other tangible fixed assets26€19k€17k▼
Current assets29/58€717k€685k▼
Stocks and contracts in progress3€124k€125k▲
Stocks30/36€124k€125k▲
Amounts receivable within one year40/41€505k€533k▲
Trade receivables40€66k€109k▲
Other amounts receivable41€439k€424k▼
Cash at bank and in hand54/58€87k€26k▼
Deferred charges and accrued income490/1€2k€2k▲
Equity and liabilities
Total equity and liabilities10/49€855k€803k▼
Equity10/15€134k€184k▲
Contributions10/11€6k€6k=
Reserves13€127k€178k▲
Non-distributable reserves130/1€2k€2k=
Reserves not available under the articles1311€2k€2k=
Tax-exempt reserves132€36k€36k=
Distributable reserves133€89k€140k▲
Amounts payable17/49€722k€618k▼
Amounts payable after more than one year17€171k€125k▼
Financial debts170/4€171k€125k▼
Amounts payable within one year42/48€551k€493k▼
Current portion of amounts payable after more than one year42€45k€45k▲
Financial debts43€6k€6k▼
Credit institutions430/8€6k-
Other loans439-€6k
Trade debts44€125k€122k▼
Suppliers440/4€125k€122k▼
Advances received on contracts in progress46-€39k
Taxes, remuneration and social security45€2k€11k▲
Taxes450/3€2k€11k▲
Other amounts payable47/48€373k€269k▼
Accrued charges and deferred income492/3€15€27▲
Income statement
Code20232024
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€21k€21k▲
Other operating charges640/8€4k€4k▲
Gross operating margin9900€66k€90k▲
Operating profit (loss)9901€42k€65k▲
Financial income75/76B€34k€26k▼
Recurring financial income75€34k€26k▼
Financial charges65/66B€38k€21k▼
Recurring financial charges65€38k€21k▼
Profit (loss) for the period before taxes9903€37k€69k▲
Income taxes67/77€6k€18k▲
Profit (loss) for the period9904€32k€51k▲
Profit (loss) for the period to be appropriated9905€32k€51k▲
Appropriation of the result
Profit (loss) to be appropriated9906€32k€51k▲
Transfer to equity691/2€32k€51k▲
To other reserves6921€32k€51k▲
Social balance
Average headcount (FTE)9087-0.0
The notes to these accounts (11 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
2026
23-09
State Gazette act
Resignation: Apowest (manager)Appointments: Apowest (director) and Geert Debaere (director) · Permanent representative: Marlies Degroote · Legal-form conversion15 facts ▸
State Gazette act
Resignation: Apowest (manager)
Appointments: Apowest (director) and Geert Debaere (director) · Permanent representative: Marlies Degroote · Legal-form conversion15 facts ▸
- General meeting, buitengewone algemene vergadering
- Legal-form conversion, besloten vennootschap
- Name change, Apotheek Godilo
- Capital conversion, statutair onbeschikbare eigen vermogensrekening
- Capital conversion, statutair onbeschikbare eigen vermogensrekening
- Capital conversion, eigen vermogensrekening niet-opgevraagde inbrengen
- Reserve release, opheffen, statutair onbeschikbare eigen vermogensrekening
- Statutes amendment
- Capital
- Director resignation, Apowest (manager)
- Director appointment, Apowest (director)
- Director appointment, Geert Debaere (director)
- +3 further facts in this act
2025
28-08
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema · 28 days late
2024
31-12
Financial
Highest result since 2018net €51k ▲60.3%
Operating result €65k, net result €51k, both a record.
31-12
Financial
Equity above €150kEq €184k ▲37.9%
2 profitable years in a row build equity to €184k.
30-08
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema · 30 days late
2023
31-12
Financial
Back to profitnet €32k
Net result €32k after one loss-making year.
31-08
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema · 31 days late
2022
31-12
Financial
Weakest financial yearnet €-14k ▼191%
Net result drops to €-14k, the lowest in the series; recovery starts the following year.
31-08
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema · 31 days late
2021
27-08
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema · 27 days late
2020
31-12
Financial
Equity above €100kEq €101k ▲6.1%
2 profitable years in a row build equity to €101k.
07-07
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
Show earlier events
2019
31-12
Financial
Back to profitnet €2k
Net result €2k after one loss-making year.
21-08
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema · 21 days late
2018
24-08
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema · 24 days late
2017
30-08
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema · 30 days late
2016
15-07
NBB filing
Annual accounts filed
fiscal year 2015 · abbreviated schema
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
2 directors, no change since 2026
Apowest
CurrentDirector · since 23-09-2026 · Legal entity · perm. rep.: Marlies Degroote
Geert Debaere
CurrentDirector · since 23-09-2026
23-09-2026
Apowest: Resigned as Manager
23-09-2026
Apowest: Appointed as Director
23-09-2026
Geert Debaere: Appointed as Director
Location & real-estate footprint
Registered office, Wevelgem · 1 establishment unit since 2005
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Bissegemstraat 388560 WevelgemGround area
757 m²
Building footprint
190 m²
Volume, LiDAR
1,156 m³
Parcel 34012C0112/00D002, Flanders · tallest building 10.7 m, ±2 floors. Linked by address, not a title deed.
1 establishment unit
APOTHEEK H. DESMET
since 20052.145.421.848
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 34012C0112/00D002 | Flanders | 757 m² | 1 · 190 m² | 10.7 m · 2 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Articles of association
Annual meeting
Last Friday of May at 20:00
Duration
Unlimited
Purpose
Het oprichten, overnemen en uitbaten van een apotheek of apotheken met alle hieronder inbegrepen activiteiten en onder meer de handel onder alle vormen, aankoop en verkoop, in- en…
Full purpose (6 activities)
- Het oprichten, overnemen en uitbaten van een apotheek of apotheken met alle hieronder inbegrepen activiteiten en onder meer de handel onder alle vormen, aankoop en verkoop, in- en uitvoer en fabricatie in farmaceutische en parafarmaceutische producten, phytotherapeutische producten, cosmetica, parfumerie, drogisterijartikelen en bandageartikelen, herboristerij, kruiden, toiletartikelen, dieetproducten, onderhoudsproducten, magistrale bereiding van allo- of homeopathische geneesmiddelen
- Iedere activiteit die met de gezondheidszorg in de ruimste zin verband houdt
- Het ondernemen van industriële, klinische, medische, biologische, scheikundige en toxicologische analyses: alles in de ruimste zin van het woord
- Alle handelingen die rechtstreeks of onrechtstreeks met dit voorwerp in verband staan, alsook zich borg stellen voor het goede verloop van verbintenissen door derde personen aangegaan
- Door middel van inbreng, fusie, inschrijving of op om het even welke andere wijze, mogen deelnemen aan alle ondernemingen, verenigingen, vennootschappen, die een gelijksoortig en bijhorend voorwerp nastreven of die eenvoudig nuttig zijn tot de algehele of gedeeltelijke verwezenlijking van haar voorwerp
- Alle commerciële, industriële, financiële, roerende en onroerende handelingen mogen verrichten in rechtstreeks of onrechtstreeks, geheel of gedeeltelijk verband met haar voorwerp of die van aard zouden zijn de verwezenlijking ervan te vergemakkelijken of uit te breiden
Other provisions of the articles (26)
- Name clause: Apotheek Godilo
- Registered office clause: Vlaams Gewest, Artikel 2
- Board rule: met of zonder beperking van duur, Artikel 12
- Board rule (2)
- Other statement (15)
- Auditor rule: hernieuwbare termijn van drie jaar, één of meerdere commissarissen
- Other statement: Artikel 21. Beraadslagingen
- Voting rule: elke aandeelhouder kan aan ieder andere persoon, al dan niet aandeelhouder, door alle middelen van overdracht, een schriftelijke volmacht geven om zich te laten…
- Other statement: de aandeelhouders kunnen, binnen de wettelijke grenzen, eenparig en schriftelijk alle besluiten nemen die tot de bevoegdheid van de algemene vergadering behoren…
- Profit allocation
- Liquidation distribution
Structure & network
Capital and shareholders
Capital over the years
- 23-09-2026 Converted to unavailable equity · 6,200 EUR
- 23-09-2026 Converted to unavailable equity · 1,860 EUR
- 23-09-2026 Converted to uncalled contributions · 12,400 EUR
Recognitions · licences · registrations
Food safety, FASFC
1 siteWevelgem2.145.421.848
Similar companies · same sector, comparable size
BREHOPHAR
BE 0885.849.827
Oostkamp · Eq €183,907
APOTHEEK VAN DER JONCKHEYD
BE 0463.247.947
Kapellen · Eq €183,880
APOTHEEK DE MEESTER
BE 0861.825.697
Turnhout · Eq €184,605
FARMA KOERSEL
BE 0452.491.241
Beringen · Eq €183,857
NZOSSHEALTH
BE 0803.966.583
Sint-Lambrechts-Woluwe · Eq €184,832
Of 5,220 companies in sector 47730 we hold annual accounts for 3,861. 3,581 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded18-01-2005
Fiscal year end31-12
Activities, NACEBEL 2025
47730Retail sale of pharmaceutical products
Sources
Crossroads Bank for EnterprisesNational Bank · 20 filingsAddress and cadastre registers
Scores and ratios are computed by Checked and are not a credit decision.